Evidence map›Paper›PMID 38679653›Full record

ArticleScientific reports2024

A national evaluation analysis and expert interview study of real-world data sources for research and healthcare decision-making.

Veronika Mikl, Dejan Baltic, Thomas Czypionka, Alexander Degelsegger-Márquez, Nikolaus Forgó, Ghazaleh Gouya-Lechner, Arnold Herzog, Peter Klimek, David Benjamin Lumenta, Bernhard Mraz and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Veronika Mikl *Gesellschaft für Pharmazeutische Medizin E.V. (GPMed), 1210, Vienna, Austria.
Dejan BalticGesellschaft für Pharmazeutische Medizin E.V. (GPMed), 1210, Vienna, Austria.
Thomas Czypionka *Institut für Höhere Studien - Institute for Advanced Studies (IHS), 1080, Vienna, Austria.
Alexander Degelsegger-MárquezGesundheit Österreich GmbH (GÖG), 1010, Vienna, Austria.
Nikolaus ForgóFaculty of Law, Department of Innovation and Digitalisation in Law, University of Vienna, 1010, Vienna, Austria.
Ghazaleh Gouya-LechnerGesellschaft für Pharmazeutische Medizin E.V. (GPMed), 1210, Vienna, Austria.
Arnold HerzogAustrian Medicines and Medical Devices Agency (AGES Medizinmarktaufsicht), 1220, Vienna, Austria.
Peter Klimek *Supply Chain Intelligence Institute Austria (ASCII), 1080, Vienna, Austria.
David Benjamin Lumenta *Research Unit for Digital Surgery, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery, Medical University of Graz, 8036, Graz, Austria.
Bernhard Mraz *Gesellschaft für Pharmazeutische Medizin E.V. (GPMed), 1210, Vienna, Austria.
Herwig OstermannGesundheit Österreich GmbH (GÖG), 1010, Vienna, Austria.
Robert ScharingerFederal Ministry of Social Affairs, Health, Care and Consumer Protection, 1010, Vienna, Austria.
Tanja StammGesellschaft für Pharmazeutische Medizin E.V. (GPMed), 1210, Vienna, Austria.
Michael Strassnig *Wiener Wissenschafts-, Forschungs- und Technologiefonds (Vienna Science and Technology Fund), 1090, Vienna, Austria.
Markus ZeitlingerGesellschaft für Pharmazeutische Medizin E.V. (GPMed), 1210, Vienna, Austria.
Johannes Pleiner-Duxneuner *Gesellschaft für Pharmazeutische Medizin E.V. (GPMed), 1210, Vienna, Austria. johannes.pleiner@gpmed.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Real-world data (RWD) can provide intel (real-world evidence, RWE) for research and development, as well as policy and regulatory decision-making along the full spectrum of health care. Despite calls from global regulators for international collaborations to integrate RWE into regulatory decision-making and to bridge knowledge gaps, some challenges remain. In this work, we performed an evaluation of Austrian RWD sources using a multilateral query approach, crosschecked against previously published RWD criteria and conducted direct interviews with representative RWD source samples. This article provides an overview of 73 out of 104 RWD sources in a national legislative setting where major attempts are made to enable secondary use of RWD (e.g. law on the organisation of research, "Forschungsorganisationsgesetz"). We were able to detect omnipresent challenges associated with data silos, variable standardisation efforts and governance issues. Our findings suggest a strong need for a national health data strategy and data governance framework, which should inform researchers, as well as policy- and decision-makers, to improve RWD-based research in the healthcare sector to ultimately support actual regulatory decision-making and provide strategic information for governmental health data policies.

Indexed as

Decision MakingAustriaDelivery of Health CareHealth PolicyHumansInformation SourcesInterviews as TopicData qualityData quality criteriaData quality recommendationsFAIR data principlesGesellschaft für Pharmazeutische MedizinGPMedHealthcare decision-makingHealth data strategyHealth data usePharmaceutical researchQuality criteria for RWD in health careReal-world dataReal-world evidenceSecondary use of health data

Identifiers

PMID38679653
PMCPMC11056370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.